The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,407
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Polyamidoamine cascade polymers mediate efficient transfection of cells in culture
Haensler, J., & Szoka, F. C. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00023a012 · Cited by 1,207
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism
zur Mühlen, A., Schwarz, C., & Mehnert, W. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00150-1 · Cited by 945
Handbook of Pharmaceutical Controlled Release Technology
Wise, D. L. (2000) · CRC Press eBooks · doi:10.1201/9781482289985 · Cited by 768
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Fu, K., Pack, D. W., Klibanov, A. M., & Langer, R. (2000) · Pharmaceutical Research · doi:10.1023/a:1007582911958 · Cited by 764
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.
McIntyre, A., Gibson, P. R., & Young, G. P. (1993) · Gut · doi:10.1136/gut.34.3.386 · Cited by 555
Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties
Jenning, V., Schäfer-Korting, M., & Gohla, S. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00223-0 · Cited by 545
Freitas, C., & Müller, R. H. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00074-5 · Cited by 483
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476
Liposome-based drug delivery in breast cancer treatment
Park, J. W. (2002) · Breast Cancer Research · doi:10.1186/bcr432 · Cited by 469
Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
Crystallization tendency and polymorphic transitions in triglyceride nanoparticles
Bunjes, H., Westesen, K., & Koch, M. H. J. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04286-5 · Cited by 425
Multidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
Wong, H. L., Bendayan, R., Rauth, A. M., Xue, H. Y., Babakhanian, K., & Wu, X. Y. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101154 · Cited by 344
Self-citationFundarò, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317
Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S. Z., & Wu, X. Y. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0282-x · Cited by 303
Self-citationDoxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Oxygen/Nitrogen Radicals: Cell Injury and Disease · doi:10.1007/978-1-4615-1087-1_13 · Cited by 296
Pratt, W. B. (1979) · Andalas University Repository (Andalas University) · Cited by 285
Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant
Müller, R. H., Rühl, D., Runge, S., Schulze-Forster, K., & Mehnert, W. (1997) · Pharmaceutical Research · doi:10.1023/a:1012043315093 · Cited by 265
Lim, S.-J., & Kim, C.-K. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00269-7 · Cited by 249
CHEN, D.-B., YANG, T.-Z., LU, W.-L., & ZHANG, Q. (2001) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.49.1444 · Cited by 243
Müller, R. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(96)04539-5 · Cited by 242
Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Hryniuk, W. M., Figueredo, A. T., & Goodyear, M. D. E. (1987) · PubMed · Cited by 227
Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles
Siekmann, B., & Westesen, K. (1994) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/0927-7765(94)80063-4 · Cited by 217
A. Dingler, R. P. B. (1999) · Journal of Microencapsulation · doi:10.1080/026520499288690 · Cited by 217
Harivardhan Reddy, L., Sharma, R. K., Chuttani, K., Mishra, A. K., & Murthy, R. S. R. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.02.028 · Cited by 212
Zara, G. P., Cavalli, R., Bargoni, A., Fundarò, A., Vighetto, D., & Gasco, M. R. (2002) · Journal of Drug Targeting · doi:10.1080/10611860290031868 · Cited by 207
Westesen, K., Siekmann, B., & Koch, M. H. J. (1993) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(93)90177-h · Cited by 206
A method to determine the ability of drugs to diffuse through the blood-brain barrier.
Seelig, A., Gottschlich, R., & Devant, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.68 · Cited by 197
In Situ Blood–Brain Barrier Transport of Nanoparticles
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003374.58641.62 · Cited by 182
Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., & Rosa Gasco, M. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00562-7 · Cited by 180
Wang, J.-X., Sun, X., & Zhang, Z.-R. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00083-8 · Cited by 179
Wong, H. L., Bendayan, R., Rauth, A. M., & Wu, X. Y. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20100 · Cited by 178
Self-citationOlbrich, C., Gessner, A., Kayser, O., & Müller, R. H. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000001832 · Cited by 175
Incorporation of cyclosporin A in solid lipid nanoparticles (SLN)
Ugazio, E., Cavalli, R., & Gasco, M. R. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00268-5 · Cited by 168
Cellular resistance to anthracyclines
Nielsen, D., Maare, C., & Skovsgaard, T. (1996) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(95)02013-6 · Cited by 167
Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, M., et al. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.026 · Cited by 165
Smith, A., & Hunneyball, L. M. (1986) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(86)90081-5 · Cited by 163
Handbook of cancer chemotherapy
(1993) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(93)90321-b · Cited by 158
Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts
Çiftçi, K., & Levy, R. J. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00623-8 · Cited by 154
Tabatt, K., Sameti, M., Olbrich, C., Müller, R. H., & Lehr, C. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2003.10.015 · Cited by 152
Preparation and characterization of solid lipid nanospheres containing paclitaxel
Cavalli, R., Caputo, O., & Gasco, M. R. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00081-6 · Cited by 149
Zara, G. P., Bargoni, A., Cavalli, R., Fundaro', A., Vighetto, D., & Gasco, M. R. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10129 · Cited by 143
A Folate Receptor?Targeted Lipid Nanoparticle Formulation for a Lipophilic Paclitaxel Prodrug
Stevens, P. J., Sekido, M., & Lee, R. J. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7667-5 · Cited by 140
Drug resistance reversal—are we getting closer?
Baird, R. D., & Kaye, S. B. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00619-1 · Cited by 130
Lim, S., Lee, M., & Kim, C. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.032 · Cited by 128
Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes
Tabatt, K., Kneuer, C., Sameti, M., Olbrich, C., Müller, R. H., Lehr, C., & Bakowsky, U. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.029 · Cited by 123
PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)
Zara, G. P., Cavalli, R., Fundaro', A., Bargoni, A., Caputo, O., & Gasco, M. R. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0509 · Cited by 122
Principles of Antineoplastic Drug Development and Pharmacology
Schilsky, R. L., Milano, G. A., & Ratain, M. J. (1996) · Cited by 115
Fischer, V., Rodríguez‐Gascón, A., Heitz, F., Tynes, R. E., Hauck, C., Cohen, D., & Vickers, A. E. M. (1998) · PubMed · Cited by 111
Planting, A. S. T., Sonneveld, P., van der Gaast, A., Sparreboom, A., van der Burg, M. E. L., Luyten, G. P. M., Leeuw, K. D., de Boer-Dennert, M. M., Wissel, P. S., Jewell, R. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0854-6 · Cited by 107
An overview of targeted treatments in cancer
Abou-Jawde, R. M., Choueiri, T. K., Alemany, C. A., & Mekhail, T. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80209-6 · Cited by 101
Li, Y., Taulier, N., Rauth, A. M., & Wu, X. Y. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9033-2 · Cited by 95
Self-citationCationic Liposome-Mediated Gene Delivery In vivo
Templeton, N. S. (2002) · Bioscience Reports · doi:10.1023/a:1020142823595 · Cited by 81
Lo, Y. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00451-2 · Cited by 63
Liu, Z., Wu, X. Y., & Bendayan, R. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9803353 · Cited by 59
Self-citationStudy of suboptimum treatment response: lessons from breast cancer
Lønning, P. E. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01022-2 · Cited by 57
Liu, Z., Ballinger, J. R., Rauth, A. M., Bendayan, R., & Wu, X. Y. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021567 · Cited by 54
Self-citationTang, A., Kopečková, P., & Kopec̆ek, J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022639701388 · Cited by 45
Principles of Cancer Chemotherapy
Ewesuedo, R. B., & Ratain, M. J. (2003) · Springer eBooks · doi:10.1007/978-3-642-55780-4_3 · Cited by 44
Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?
Gieseler, F., Rudolph, P., Kloeppel, G., & Fölsch, U. R. (2003) · International Journal of Colorectal Disease · doi:10.1007/s00384-003-0496-x · Cited by 36
Campone, M., Vavasseur, F., Cabellec, M. L., Méflah, K., Vallette, F. M., & Oliver, L. (2001) · Leukemia · doi:10.1038/sj.leu.2402222 · Cited by 30
Searching for the Magic Bullet Against Cancer: The Butyrate Saga
Sontini, V., Gozzini, A., Scappini, B., Grossi, A., & Ferrini, P. R. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109064584 · Cited by 29
Cited by
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Metadata
- Authors
- WONG, H., BENDAYAN, R., RAUTH, A., LI, Y., & WU, X.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2007-07-10
- Volume
- 59
- Issue
- 6
- Pages
- 491-504
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2044072446
- Cited by
- 578
- References
- 78
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.